chr7:140781602:C>T Detail (hg38) (BRAF)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr7:140,481,402-140,481,402 View the variant detail on this assembly version. |
| hg38 | chr7:140,781,602-140,781,602 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
| RefSeq | NM_004333.4:c.1526G>A | NP_004324.2:p.Gly509Glu |
| Ensemble | ENST00000288602.11:c.1526G>A | ENST00000288602.11:p.Gly509Glu |
| ENST00000496384.7:c.1406G>A | ENST00000496384.7:p.Gly469Glu |
Summary
MGeND
| Clinical significance |
|
| Variant entry | 2 |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
| JP | HGVD:[No Data.] |
| ToMMo:[No Data.] | |
| NCBN:[No Data.] | |
| NCBN(Hondo):[No Data.] | |
| NCBN(Ryukyu):[No Data.] | |
| East asia | ExAC:<0.001 |
Prediction
ClinVar
| Clinical Significance |
|
| Review star | ![]() |
| Show details | |
Disease area statistics
MGeND
| Clinical significance | Last evaluated | Condition | Origin | Submission ID | Submitter | Institute | Citation | Comment | Image |
|---|---|---|---|---|---|---|---|---|---|
|
|
2017/11/30 | lung adenocarcinoma (metastasis) |
|
MGS000017
(TMGS000052) |
Kohei Miyazono | Tokyo University | |||
|
|
2017/03/30 | cardiofaciocutaneous syndrome |
|
MGS000001
(TMGS000137) |
Kenjiro Kosaki | Keio University |
ClinVar
| Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
|---|---|---|---|---|---|
|
|
2024-03-17 | criteria provided, multiple submitters, no conflicts | cardiofaciocutaneous syndrome 1 |
|
Detail |
|
|
2023-05-18 | criteria provided, single submitter | RASopathy |
|
Detail |
|
|
2017-04-03 | reviewed by expert panel | Cardio-facio-cutaneous syndrome |
|
Detail |
|
|
2022-06-13 | criteria provided, multiple submitters, no conflicts | not provided |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided | Malignant melanoma of skin |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided |
|
Detail | |
|
|
2016-05-31 | no assertion criteria provided | Neoplasm of the large intestine |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided | Squamous cell lung carcinoma |
|
Detail |
|
|
2015-07-14 | no assertion criteria provided | melanoma |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided | prostate adenocarcinoma |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided | lung adenocarcinoma |
|
Detail |
|
|
2016-05-31 | no assertion criteria provided |
|
Detail | |
|
|
2016-05-31 | no assertion criteria provided | multiple myeloma |
|
Detail |
|
|
2017-03-10 | criteria provided, single submitter | not specified |
|
Detail |
|
|
2021-03-05 | criteria provided, single submitter | Noonan syndrome and Noonan-related syndrome |
|
Detail |
|
|
criteria provided, single submitter | Noonan syndrome 7 |
|
Detail | |
|
|
no assertion criteria provided | Noonan syndrome 1 |
|
Detail |
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| skin melanoma | Sorafenib | D |
|
|
Sensitivity/Response | Somatic | 3 | 18794803 | Detail |
| skin melanoma | U0126 | D |
|
|
Somatic | 3 | 18794803 | Detail |
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.242 | Lymphoma, Non-Hodgkin | NA | CLINVAR | Detail | |
| 0.567 | Cardio-facio-cutaneous syndrome | NA | CLINVAR | Detail | |
| 0.049 | Metastatic melanoma | Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of ... | BeFree | 26070258 | Detail |
| 0.015 | Malignant neoplasm of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
| 0.125 | Carcinoma of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
| 0.131 | Non-small cell lung carcinoma | NA | CLINVAR | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations ... | CIViC Evidence | Detail |
| In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations ... | CIViC Evidence | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Cardiofaciocutaneous syndrome 1 | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND RASopathy | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Cardio-facio-cutaneous syndrome | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND not provided | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Malignant melanoma of skin | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Transitional cell carcinoma of the bladder | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Neoplasm of the large intestine | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Squamous cell lung carcinoma | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Melanoma | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Prostate adenocarcinoma | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Lung adenocarcinoma | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Squamous cell carcinoma of the skin | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Multiple myeloma | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND not specified | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Noonan syndrome and Noonan-related syndrome | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Noonan syndrome 7 | ClinVar | Detail |
| NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu) AND Noonan syndrome 1 | ClinVar | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of therapy with BRAF in... | DisGeNET | Detail |
| The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
| The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs121913355 dbSNP
- Genome
- hg38
- Position
- chr7:140,781,602-140,781,602
- Variant Type
- snv
- Reference Allele
- C
- Alternative Allele
- T
- East Asian Chromosome Counts (ExAC)
- 8654
- East Asian Allele Counts (ExAC)
- 0
- East Asian Heterozygous Counts (ExAC)
- 0
- East Asian Homozygous Counts (ExAC)
- 0
- East Asian Allele Frequency (ExAC)
- 0.0
- Chromosome Counts in All Race (ExAC)
- 121388
- Allele Counts in All Race (ExAC)
- 1
- Heterozygous Counts in All Race (ExAC)
- 1
- Homozygous Counts in All Race (ExAC)
- 0
- Allele Frequency in All Race (ExAC)
- 8.238046594391538E-6
- Variant (CIViC) (CIViC Variant)
- G469E
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/993
- Summary (CIViC Variant)
- The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.
Genome browser
